Profusa Partners with MedSell to Commercialize Lumee™ Monitoring in France
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Source: Newsfilter
- Market Expansion: Profusa's partnership with MedSell introduces Lumee™ oxygen monitoring in France, expected to cover approximately 200,000 CLI cases annually, significantly enhancing the company's penetration in the European market.
- Clinical Need Fulfillment: The Lumee™ device measures tissue oxygen perfusion before and after revascularization, addressing the clinical needs of patients with complex chronic wounds in France, thereby enhancing decision support for clinicians.
- Revenue Projections: Profusa anticipates achieving $200 to $250 million in revenue by 2030, with potential revenues of $0.5 to $2 million in 2026, indicating strong market potential.
- Strategic Collaboration: The collaboration with Dr. Yann Gouëffic at Groupe Hospitalier Paris Saint Joseph further advances the application of Lumee technology in clinical studies, expected to enhance the company's market influence in France.
Analyst Views on PFSA
About PFSA
Profusa, Inc. is a commercial stage digital health company. The Company is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
